AR065818A1 - Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana - Google Patents
Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humanaInfo
- Publication number
- AR065818A1 AR065818A1 ARP080101195A ARP080101195A AR065818A1 AR 065818 A1 AR065818 A1 AR 065818A1 AR P080101195 A ARP080101195 A AR P080101195A AR P080101195 A ARP080101195 A AR P080101195A AR 065818 A1 AR065818 A1 AR 065818A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- antibody
- combinations
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 abstract 4
- 102000043959 human IL18 Human genes 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229940115080 doxil Drugs 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000639 pazopanib Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 229960000303 topotecan Drugs 0.000 abstract 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de combinaciones de la IL-18 humana en el tratamiento de diversas formas de tumores solidos y linfomas. En particular, la presente se refiere a: (1) combinaciones de la IL-18 humana con anticuerpos monoclonales contra antígenos que se expresanen la superficie de células cancerosas; y (2) combinaciones de IL-18 humana con agentes terapéuticos. Reivindicacion 1: Un método para tratar el cáncer en un paciente necesitado de ello, que comprende la etapa de: administrar separadamente alpaciente una composicion que comprende: (1) un polipéptido (SEQ ID N°:1) de la IL-18 humana en combinacion con un vehículo y; y (ii) un anticuerpo monoclonal contra un antígeno que se expresa en la superficie de una célula cancerosa, en el que elanticuerpo tiene una funcion de efector de citotoxicidad dependiente de anticuerpos mediada por células (ADCC), y en el que el anticuerpo no es un anticuerpo anti-CD20. Reivindicacion 13: El método segun la reivindicacion 9, en el que el agentequimioterapéutico se elige del grupo de: doxil, topotecán, fármacos que alteran el DNA, carboplatino, antimetabolitos, gemcitabina, fármacos que impiden la division celular, vincristina, agentes antiangiogénicos, y pazopanib.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89685507P | 2007-03-23 | 2007-03-23 | |
| US95200207P | 2007-07-26 | 2007-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065818A1 true AR065818A1 (es) | 2009-07-01 |
Family
ID=39788932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101155A AR065803A1 (es) | 2007-03-23 | 2008-03-19 | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| ARP080101195A AR065818A1 (es) | 2007-03-23 | 2008-03-25 | Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101155A AR065803A1 (es) | 2007-03-23 | 2008-03-19 | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20090035258A1 (es) |
| EP (3) | EP2129398A4 (es) |
| JP (2) | JP2010522200A (es) |
| KR (2) | KR20100015798A (es) |
| CN (1) | CN101678102A (es) |
| AR (2) | AR065803A1 (es) |
| AU (2) | AU2008231025A1 (es) |
| BR (2) | BRPI0809079A2 (es) |
| CA (2) | CA2681827A1 (es) |
| CL (2) | CL2008000818A1 (es) |
| CR (2) | CR10996A (es) |
| DO (2) | DOP2009000208A (es) |
| EA (2) | EA200970885A1 (es) |
| IL (2) | IL200525A0 (es) |
| MA (2) | MA31265B1 (es) |
| MX (2) | MX2009010269A (es) |
| NZ (1) | NZ579179A (es) |
| PE (2) | PE20090190A1 (es) |
| SG (1) | SG171674A1 (es) |
| TW (2) | TW200906436A (es) |
| WO (2) | WO2008118736A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102206277A (zh) * | 2000-02-10 | 2011-10-05 | 雅培制药有限公司 | 结合人白介素-18的抗体及制备和使用方法 |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| PE20090190A1 (es) * | 2007-03-23 | 2009-03-22 | Smithkline Beecham Corp | Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18 |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| LT3134124T (lt) | 2014-04-25 | 2019-05-27 | Pierre Fabre Médicament | Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui |
| PT3134125T (pt) | 2014-04-25 | 2020-01-13 | Pf Medicament | Conjugado-fármaco-anticorpo e sua utilização para o tratamento de cancro |
| CA2957387A1 (en) * | 2014-08-07 | 2016-02-11 | Hyogo College Of Medicine | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody |
| WO2016126615A1 (en) * | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US20240368247A1 (en) * | 2020-12-02 | 2024-11-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists |
| WO2025033330A1 (ja) * | 2023-08-04 | 2025-02-13 | 医療革新国際連携株式会社 | キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
| TW581771B (en) | 1994-11-15 | 2004-04-01 | Hayashibara Biochem Lab | Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide |
| JP4004088B2 (ja) | 1995-09-26 | 2007-11-07 | 株式会社林原生物化学研究所 | 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質 |
| US7135458B1 (en) * | 1995-11-15 | 2006-11-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use |
| US5680795A (en) | 1995-07-05 | 1997-10-28 | Norco Inc. | Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers |
| JP4024366B2 (ja) * | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | ポリペプチド |
| US6787132B1 (en) * | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| TWI227136B (en) * | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| PL208592B1 (pl) * | 2000-06-15 | 2011-05-31 | Smithkline Beecham Corp | Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18 |
| US20020094323A1 (en) * | 2000-10-12 | 2002-07-18 | Kristoffer Hellstrand | Methods and compositions for promoting the maturation of monocytes |
| CN101914158A (zh) * | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
| US20040001828A1 (en) * | 2002-02-21 | 2004-01-01 | Joseph Tuscano | Treatment methods using anti-CD22 antibodies |
| ATE497778T1 (de) * | 2002-09-16 | 2011-02-15 | Agennix Inc | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus |
| WO2004032962A1 (en) * | 2002-10-08 | 2004-04-22 | Immunomedics, Inc. | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |
| SI1558648T1 (sl) * | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| WO2004091517A2 (en) * | 2003-04-15 | 2004-10-28 | Smithkline Beecham Corporation | Conjugates comprising human il-18 and substitution mutants thereof |
| US20050075277A1 (en) * | 2003-07-10 | 2005-04-07 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
| US7109304B2 (en) * | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| RU2412199C2 (ru) * | 2005-04-18 | 2011-02-20 | Ново Нордиск А/С | Варианты ил-21 |
| KR20080030673A (ko) * | 2005-07-21 | 2008-04-04 | 젠맵 에이/에스 | Ｆｃ 수용체와 결합하는 항체 약품 성분에 대한 효력 검정 |
| WO2008008981A1 (en) * | 2006-07-13 | 2008-01-17 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| CA2662609A1 (en) * | 2006-09-14 | 2008-03-20 | The Trustees Of The University Of Pennsylvania | Modulation of regulatory t cells by human il-18 |
| PE20090190A1 (es) * | 2007-03-23 | 2009-03-22 | Smithkline Beecham Corp | Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18 |
-
2008
- 2008-03-19 PE PE2008000506A patent/PE20090190A1/es not_active Application Discontinuation
- 2008-03-19 AR ARP080101155A patent/AR065803A1/es not_active Application Discontinuation
- 2008-03-20 EP EP08744109A patent/EP2129398A4/en not_active Withdrawn
- 2008-03-20 CL CL200800818A patent/CL2008000818A1/es unknown
- 2008-03-20 SG SG201103315-6A patent/SG171674A1/en unknown
- 2008-03-20 BR BRPI0809079-3A patent/BRPI0809079A2/pt not_active IP Right Cessation
- 2008-03-20 CA CA002681827A patent/CA2681827A1/en not_active Abandoned
- 2008-03-20 WO PCT/US2008/057620 patent/WO2008118736A1/en not_active Ceased
- 2008-03-20 NZ NZ579179A patent/NZ579179A/en not_active IP Right Cessation
- 2008-03-20 MX MX2009010269A patent/MX2009010269A/es not_active Application Discontinuation
- 2008-03-20 AU AU2008231025A patent/AU2008231025A1/en not_active Abandoned
- 2008-03-20 CA CA002681851A patent/CA2681851A1/en not_active Abandoned
- 2008-03-20 KR KR1020097022076A patent/KR20100015798A/ko not_active Withdrawn
- 2008-03-20 EP EP10192703A patent/EP2338514A1/en not_active Withdrawn
- 2008-03-20 US US12/052,278 patent/US20090035258A1/en not_active Abandoned
- 2008-03-20 EA EA200970885A patent/EA200970885A1/ru unknown
- 2008-03-20 EP EP08744104A patent/EP2136841A4/en not_active Withdrawn
- 2008-03-20 US US12/532,776 patent/US20100196310A1/en not_active Abandoned
- 2008-03-20 WO PCT/US2008/057615 patent/WO2008118733A2/en not_active Ceased
- 2008-03-20 KR KR1020097019795A patent/KR20100014530A/ko not_active Withdrawn
- 2008-03-20 AU AU2008231114A patent/AU2008231114A1/en not_active Abandoned
- 2008-03-20 US US12/052,120 patent/US20080274078A1/en not_active Abandoned
- 2008-03-20 JP JP2009554732A patent/JP2010522200A/ja active Pending
- 2008-03-20 US US12/532,727 patent/US20100111945A1/en not_active Abandoned
- 2008-03-20 CN CN200880017106A patent/CN101678102A/zh active Pending
- 2008-03-20 BR BRPI0808943-4A patent/BRPI0808943A2/pt not_active IP Right Cessation
- 2008-03-20 EA EA200970884A patent/EA200970884A1/ru unknown
- 2008-03-20 JP JP2010501096A patent/JP2010522239A/ja not_active Withdrawn
- 2008-03-20 MX MX2009010271A patent/MX2009010271A/es unknown
- 2008-03-21 TW TW097109963A patent/TW200906436A/zh unknown
- 2008-03-24 CL CL200800842A patent/CL2008000842A1/es unknown
- 2008-03-24 TW TW097110406A patent/TW200904469A/zh unknown
- 2008-03-24 PE PE2008000532A patent/PE20090184A1/es not_active Application Discontinuation
- 2008-03-25 AR ARP080101195A patent/AR065818A1/es not_active Application Discontinuation
-
2009
- 2009-08-20 IL IL200525A patent/IL200525A0/en unknown
- 2009-08-26 CR CR10996A patent/CR10996A/es not_active Application Discontinuation
- 2009-08-28 DO DO2009000208A patent/DOP2009000208A/es unknown
- 2009-09-10 IL IL200863A patent/IL200863A0/en unknown
- 2009-09-18 DO DO2009000220A patent/DOP2009000220A/es unknown
- 2009-09-24 MA MA32235A patent/MA31265B1/fr unknown
- 2009-09-24 MA MA32234A patent/MA31264B1/fr unknown
- 2009-10-23 CR CR11075A patent/CR11075A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065818A1 (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana | |
| Raghani et al. | Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies | |
| JP7295283B2 (ja) | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 | |
| PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| MX2012006420A (es) | Metodos para mejorar terapia con anticuerpos antitumor. | |
| EP4477270A3 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| PE20211915A1 (es) | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso | |
| JP2018510881A5 (es) | ||
| AR074219A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| BRPI0909227B8 (pt) | uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) | |
| FI3890740T3 (fi) | CD70 ja venetoklaksi, BCL-2-estäjä, yhdistelmähoito akuutin myelooisen leukemian hoitoon | |
| WO2020092848A3 (en) | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen | |
| PE20191328A1 (es) | Conjugados de farmacos y anticuerpos anti-ccr7 | |
| AR071733A1 (es) | Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma | |
| MX2022007107A (es) | Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas. | |
| JP2023065373A (ja) | 薬物の治療可能性を改善するためのｏアセチル化ｇｄ２ガングリオシドに対する抗体の使用 | |
| US20180289797A1 (en) | Cytotoxic immunostimulating particles and uses thereof | |
| WO2013170263A3 (en) | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics | |
| WO2024006925A3 (en) | Dosing regimens for cd19-directed cancer immunotherapy | |
| WO2017137595A3 (en) | Cancer treatment using nk cells | |
| ZA202206323B (en) | Treatment involving immune effector cells genetically modified to express antigen receptors | |
| ES3010637T3 (en) | B-cell depletion as a diagnostic marker | |
| JP7793985B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| AR086738A1 (es) | Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |